Initial Chemotherapeutic Doses and Long-Term Survival in Limited Small-Cell Lung Cancer

Publisher Website
Google Scholar
Abstract
We previously reported that in a multicenter, randomized trial that involved 105 patients with limited small-cell lung cancer, higher initial doses of cyclophosphamide and cisplatin improved overall survival.1 The study was stopped early at the recommendation of an independent data-monitoring committee, and the median duration of follow-up at the time of publication was 33 months.2 To evaluate whether these findings persisted over the long term, we reevaluated the patients after a median follow-up period of 11 years.